Ditchcarbon
  • Contact
  1. Organizations
  2. Shanghai Henlius Biotech
Public Profile
Pharmaceutical Preparation Manufacturing
CN
updated a month ago

Shanghai Henlius Biotech

Company website

Shanghai Henlius Biotech, also known as Henlius, is a prominent biopharmaceutical company headquartered in Shanghai, China. Founded in 2010, the company has rapidly established itself in the biotechnology industry, focusing on the research, development, and manufacturing of innovative monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. With a strong operational presence in both domestic and international markets, Henlius has achieved significant milestones, including the successful launch of its flagship products, which are distinguished by their high quality and affordability. The company is recognised for its commitment to advancing biopharmaceutical solutions, positioning itself as a key player in the global market. Henlius continues to expand its portfolio, aiming to enhance patient outcomes through cutting-edge therapies.

DitchCarbon Score

How does Shanghai Henlius Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

42

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Shanghai Henlius Biotech's score of 42 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.

62%

Let us know if this data was useful to you

Shanghai Henlius Biotech's reported carbon emissions

In 2024, Shanghai Henlius Biotech reported total carbon emissions of approximately 20,770,400 kg CO2e, with Scope 1 emissions at about 6,531,160 kg CO2e and Scope 2 emissions at around 14,239,240 kg CO2e. Additionally, Scope 3 emissions related to waste generated in operations were approximately 347,190 kg CO2e. This represents a slight decrease from 2023, where total emissions were about 21,973,000 kg CO2e, with Scope 1 at 6,908,630 kg CO2e and Scope 2 at 15,064,370 kg CO2e. Shanghai Henlius Biotech's emissions data is cascaded from its parent company, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., reflecting a corporate family relationship. The company has not set specific reduction targets under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment. Overall, while the company has made progress in managing its carbon footprint, the absence of formal reduction targets suggests that further initiatives may be necessary to align with industry standards for climate action.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20202021202220232024
Scope 1
5,534,750
0,000,000
0,000,000
0,000,000
0,000,000
Scope 2
14,133,210
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
-
000,000
000,000
000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Shanghai Henlius Biotech's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Shanghai Henlius Biotech is in CN, which we do not have grid emissions data for.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Shanghai Henlius Biotech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 hours ago

Vertex Pharmaceuticals

US
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Innovent Biologics

CN
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Lepu Medical Technology (Beijing) Co., Ltd.

CN
•
Medical, precision and optical instruments, watches and clocks (33)
Updated about 1 month ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251028.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy